Recent General Brain Cancer News

Addition of Temodar® to Radiation in Glioma: New Standard of Care

(January 19, 2017)

The addition of the chemotherapy agent, Temodar® (temozolomide), to radiation therapy has demonstrated a huge survival benefit compared to treatment with radiation therapy alone among patients with newly... Continue Reading

Temodar® After Radiation Improves Survival in Anaplastic Gliomas

(June 7, 2016)

The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic... Continue Reading

Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma

(May 23, 2016)

The United States Food and Drug Administration (FDA) has granted “breakthrough status” designation for the treatment of glioblastoma containing a genetically modified poliovirus. Glioblastoma is an... Continue Reading

Optune Approved for Newly Diagnosed Glioblastoma Multiforme

(October 22, 2015)

The United States Food and Drug Administration has expanded the approval of the Optune device for the treatment of patients with newly diagnosed glioblastoma multiforme. Glioblastoma multiforme (GBM) is... Continue Reading

Researchers Recruit Herpes Virus as Part of Brain Cancer Treatment

(July 13, 2015)

A therapy that uses the herpes virus to make tumors more vulnerable to treatment appears promising in the treatment of glioblastoma multiforme (GBM), a form of brain cancer. These findings were presented... Continue Reading

Rintega® Improves Survival in Patients with Glioblastoma Multiforme

(July 1, 2015)

The immunotherapy drug Rintega® (rindopepimut) appears to improve survival among patients with relapsed glioblastoma multiforme (GBM) brain cancer. These findings were presented at 2015 Annual Meeting... Continue Reading

Danish Study Suggests Contraceptive Use Increases Risk of Brain Cancer

(February 3, 2015)

The results of a recently published clinical study suggest that taking the birth control pill for at least five years may double the risk of developing a glioblastoma multiforme (GBM), a rare but often... Continue Reading

DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial

(September 19, 2014)

DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company’s lead product, DNX-2401, a replication competent adenovirus plus gamma... Continue Reading

Chemotherapy Following Radiation Improves Outcomes in Low Grade Glioblastoma

(June 24, 2014)

According to results recently presented at the 2014 annual meeting of the American Society of Clinical Onoclogy, patients with low-grade glioblastom multiforme (GBM) benefited from chemotherapy following... Continue Reading

Follow-Up Study Shows ICT-107 Vaccine Fails to Extend Survival in GBM

(January 27, 2014)

Despite promising results in a phase I trial, the vaccine ICT-107 failed to significantly prolong overall survival in patients with glioblastoma multiforme in a follow-up phase II trial.[1] Glioblastoma... Continue Reading

Next Page »